RxDoctor Payments Data

Daniel Mitchell

Dermatology · Thomasville, GANPI 1447219548

Payments from drug & device makers

$3,981in general payments, 2019–2025

Across 152 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$911
  • Regeneron Healthcare Solutions, Inc.$643
  • Johnson & Johnson$462
  • LEO Pharma Inc.$370
  • Pfizer$321
  • Amgen$224
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,35484%
  • Education$62616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,981 in reported general payments places this provider in the 45th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$412,922
Medicare patients
1,037
Services billed
7,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa26$542,618
RinvoqUpadacitinib34$246,677
ThalomidThalidomide14$120,053
Dupixent PenDupilumab22$82,639
Dupixent SyringeDupilumab14$52,511
Clobetasol Propionate178$6,476
Triamcinolone Acetonide392$5,818
Doxepin Hcl239$3,604
Ketoconazole172$2,747
Hydrocortisone170$2,186
Minoxidil81$1,818
Doxycycline Monohydrate109$1,750
Imiquimod56$1,652
Fluocinonide41$1,585
Tacrolimus14$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$911$246,67734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 345 dermatology providers in Georgia.

Other dermatology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →